Latest Operating Expenses News

CD Private Equity Fund I reported a $2.6 million net loss for the half-year ended 30 September 2025, driven by foreign exchange impacts and fair value adjustments, while distributing 8 cents per unit amid ongoing portfolio realisations.

Amplia Therapeutics reported a $4.18 million half-year loss but bolstered its cash reserves with a $27.6 million capital raise to advance clinical trials of its lead drug narmafotinib, showing encouraging interim data in pancreatic cancer.

SDI Limited reported a steady FY2025 with a slight profit increase, driven by growth in aesthetic and whitening products and the launch of its new amalgam replacement, Stela. The company also announced plans for a new factory to boost production capacity.

Rumble Resources’ latest Scoping Study reveals a promising underground gold mining project at Western Queen South with low capital costs and strong financial returns, setting the stage for rapid development and potential resource expansion.

HUB24 Limited showcased strong growth and strategic innovation at its 2025 Investor Strategy Day, highlighting market leadership and ambitious expansion plans across wealth management technology.

Advanced Innergy Holdings Ltd (ASX, AIH) reported unaudited proforma FY25 results exceeding prospectus forecasts, driven by strong organic growth and the strategic acquisition of Ovun. The company reaffirms its FY26 guidance, supported by a robust orderbook and pipeline.

Provaris Energy’s 2025 AGM highlights strategic progress in hydrogen and CO2 storage technologies, focusing on European market expansion and a refined licensing business model.

InhaleRX Limited has announced a non-renounceable entitlement offer to raise approximately $247,668 by issuing nearly 10 million new shares at 2.5 cents each, accompanied by free attaching options. The offer opens on 5 December and closes on 17 December 2025.

Straker Limited has significantly narrowed its interim loss despite a 15% revenue decline, driven by cost efficiencies and the absence of prior non-cash charges. The company also renewed a strategic $28 million partnership with IBM, reinforcing its AI language technology ambitions.

Fisher & Paykel Healthcare reported a robust 14% revenue increase and a 39% jump in net profit for the first half of fiscal 2026, driven by strong clinical adoption and product innovation.

IPD Group’s 2025 AGM reveals robust FY25 financial results driven by data centre and electrification sectors, alongside operational efficiencies and sustainability strides. The company signals continued momentum into FY26 with positive earnings guidance.

Aroa Biosurgery has reported a strong first half for FY26, with 14% revenue growth driven by its Myriad product line and a return to positive EBITDA. The company also secured relief from ASX quarterly reporting requirements, signaling improved financial stability.